论文部分内容阅读
BRAF突变发生于5%~11%的转移性结直肠癌患者。该研究分析了BRAF突变患者转移灶切除术后的临床病理因素、PIK3CA突变频率以及预后情况。研究通过回顾性的对2009年至2012年单中心1941例转移性结直肠癌患者行KRAS/BRAF突变检测,共检出92例患者含BRAF突变。2011年423例BRAF野生型转移性肠癌患者作为对照组。研究发现在转移性大肠癌中,与BRAF野生型组相比,BRAF突变型与确诊时高龄、女性、肿瘤位于右侧以及低分化、粘液组织形态更加相关。BRAF突变更多出现于肠癌分期III期、T4期患者。PIK3C与5%的BRAF突变共存,与17%的KRAS突变共存,与4%的BRAF/KRAS共突变共存。BRAF突变的患者一般不只局限于肝转移,更容易出现腹膜转移。研究人员进一
BRAF mutations occur in 5% to 11% of metastatic colorectal cancer patients. The study analyzed the clinicopathologic factors, the frequency of PIK3CA mutations and the prognosis of patients with BRAF mutations after resection of the metastases. In a retrospective review of KRAS / BRAF mutations in 1941 single-center patients with metastatic colorectal cancer between 2009 and 2012, 92 BRAF-containing mutations were detected. In 2011, 423 patients with BRAF wild-type metastatic colorectal cancer served as the control group. In metastatic colorectal cancer, the BRAF mutation was more associated with older, more female patients with tumors located on the right and with poorly differentiated, mucinous histology in metastatic colorectal cancer than in the BRAF wild-type group. BRAF mutations appear more in colorectal cancer stage III, T4 patients. PIK3C co-existed with 5% of BRAF mutations and coexisted with 17% of KRAS mutations coexisting with 4% of BRAF / KRAS co-mutations. Patients with BRAF mutations are generally not limited to liver metastases and are more prone to peritoneal metastases. Researchers into one